Generic drug maker Mylan Inc. today reported net income for the second quarter of $58.1 million, or 19 cents per share, up from a loss of $16.3 million, or 5 cents, a year earlier when it took charges for the acquisition of Germany-based Merck Generics.
Revenue rose 5 percent to $1.27 billion from $1.2 billion in the same period last year.
Excluding special items, Mylan earned 32 cents per share, in line with Wall Street estimates.
"This was yet another successful quarter on many fronts for Mylan," Chairman and CEO Robert Coury said in a statement.
Based on expectations for stronger results for the second half of the year, he said Mylan was raising its full-year earnings guidance to a range of $1.13 to $1.20 per share, excluding special items, up from the previous estimated range of $1 to $1.10.
Second-quarter profits of $58.1 million included "other income" of $25.3 million, which included a favorable adjustment of $13.9 million to the company's restructuring reserve and a gain of about $10.4 million on the termination of two 50 percent-owned joint ventures, Mylan said.
During a conference call with analysts, Mr. Coury said he would not take questions concerning an internal report that detailed a recent breach in quality control at the company's Morgantown, W.Va., pharmaceutical plant.
"I would like to remind everyone of Mylan's 48-year exemplary track record," he said. "Mylan, and especially Morgantown, has always been recognized as the gold standard when it comes to quality."
The facility is being investigated by the Food and Drug Administration. The probe follows a story in Sunday's Pittsburgh Post-Gazette based on Mylan's report that said workers sidestepped computer-generated warnings about potential problems with the medications they were making. Mylan's report called the problem "pervasive" and "very serious," involving "falsifying information" and "altering product." The report said no medications were compromised by the breach.
Shares rose 3 percent, or 42 cents, to $13.33 in early trading today.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.